A monoclonal antibody specifically binding nicotine, wherein said monoclonal antibody is specifically binding -(-)-nicotine and -(+)-nicotine, and wherein said monoclonal antibody is a human monoclonal antibody, and (a) wherein said monoclonal antibody comprises at least one heavy chain variable region (HCVR), wherein said HCVR comprises: (i) one heavy chain complementarity determining region (HC CDR)1, wherein said HC CDR1 consists of the peptide of SEQ ID NO:1; (ii) one HC CDR2, wherein said HC CDR2 consists of the peptide of SEQ ID NO:2; and (iii) one HC CDR3, wherein said HC CDR3 consists of the peptide of any one of SEQ ID NOs 3 and 4; preferably wherein said HC CDR3 consists of the peptide of SEQ ID NO:3, and (b) wherein said monoclonal antibody comprises at least one light chain variable region (LCVR,) wherein said LCVR comprises: (i) one light chain complementarity determining region (LC CDR)1, wherein said LC CDR1 consists of the peptide of any one of SEQ ID NOs 5, 6, and 7, preferably wherein said LC CDR1 consists of the peptide of SEQ ID NO:5; (ii) one LC CDR2, wherein said LC CDR2 consists of the peptide of SEQ ID NO:8; (iii) one LC CDR3, wherein said LC CDR3 consists of the peptide of any one of SEQ ID NOs 9 and 10, preferably wherein said LC CDR3 consists of the peptide of SEQ ID NO:9. (a) wherein said monoclonal antibody comprises at least one heavy chain variable region (HCVR), wherein said HCVR comprises: (i) one heavy chain complementarity determining region (HC CDR)1, wherein said HC CDR1 consists of the peptide of SEQ ID NO:1; (ii) one HC CDR2, wherein said HC CDR2 consists of the peptide of SEQ ID NO:2; and (iii) one HC CDR3, wherein said HC CDR3 consists of the peptide of any one of SEQ ID NOs 3 and 4; preferably wherein said HC CDR3 consists of the peptide of SEQ ID NO:3, and (i) one heavy chain complementarity determining region (HC CDR)1, wherein said HC CDR1 consists of the peptide of SEQ ID NO:1; (ii) one HC CDR2, wherein said HC CDR2 consists of the peptide of SEQ ID NO:2; and (iii) one HC CDR3, wherein said HC CDR3 consists of the peptide of any one of SEQ ID NOs 3 and 4; preferably wherein said HC CDR3 consists of the peptide of SEQ ID NO:3, and (b) wherein said monoclonal antibody comprises at least one light chain variable region (LCVR,) wherein said LCVR comprises: (i) one light chain complementarity determining region (LC CDR)1, wherein said LC CDR1 consists of the peptide of any one of SEQ ID NOs 5, 6, and 7, preferably wherein said LC CDR1 consists of the peptide of SEQ ID NO:5; (ii) one LC CDR2, wherein said LC CDR2 consists of the peptide of SEQ ID NO:8; (iii) one LC CDR3, wherein said LC CDR3 consists of the peptide of any one of SEQ ID NOs 9 and 10, preferably wherein said LC CDR3 consists of the peptide of SEQ ID NO:9. (i) one light chain complementarity determining region (LC CDR)1, wherein said LC CDR1 consists of the peptide of any one of SEQ ID NOs 5, 6, and 7, preferably wherein said LC CDR1 consists of the peptide of SEQ ID NO:5; (ii) one LC CDR2, wherein said LC CDR2 consists of the peptide of SEQ ID NO:8; (iii) one LC CDR3, wherein said LC CDR3 consists of the peptide of any one of SEQ ID NOs 9 and 10, preferably wherein said LC CDR3 consists of the peptide of SEQ ID NO:9.